

- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
 Scalzo, M., Biava, M., Porretta, G. C. & Cerreto, F. (1991). *QSAR: Rational Approaches on the Design of Bioactive Compounds*, pp. 389–392. Amsterdam: Elsevier.
 Toupet, L., Mazarri, M., Texier, F. & Carrie, R. (1991). *Acta Cryst.* **C47**, 1528–1531.

which isomer was formed as the major product in these cycloadditions, the reaction with the nitrone (*1a*) ($\text{Ar} = 3\text{-O}_2\text{NC}_6\text{H}_4$) was carried out. This gave a solid mixture of the (*E*)- and (*Z*)-isoxazolidines, (*2*), from which the major isomer was obtained on crystallization and identified as the (*Z*)-isomer, (*2a*).

Acta Cryst. (1995). **C51**, 1434–1435

(*Z*)-2-(4-Fluorophenyl)-3-(3-nitrophenyl)-5-phenylisoxazolidine: the Major Isomer Formed by 1,3-Dipolar Addition of an Arylnitron to Styrene

R. E. BANKS, R. A. DUBOISSON, R. G. PRITCHARD AND A. E. TIPPING

Department of Chemistry, University of Manchester Institute of Science and Technology, PO Box 88, Manchester M60 1QD, England

(Received 8 August 1994; accepted 19 December 1994)

Abstract

In the title molecule, $C_{21}H_{17}FN_2O_3$, the five-membered ring adopts an envelope conformation, folded between sites 2 and 5, with a flap angle of 42.0° . This configuration places the three substituents in axial positions with the fluorophenyl group attached to the N atoms *trans* to the other two aromatic rings.

Comment

The structure determination reported here was carried out as part of a detailed investigation into 1,3-dipolar cycloadditions of fluorine-containing aryl-nitrone to alkenes to afford isoxazolidines (DuBoisson, 1986). Such additions involving nitrone of type $\text{ArCH}=\text{N}^+(\text{O}^-)\text{C}_6\text{H}_4\text{F}-p$ (*1*) ($\text{Ar} = \text{C}_6\text{H}_5$, $4\text{-HO-C}_6\text{H}_4$, $4\text{-MeOC}_6\text{H}_4$) gave mixtures of (*E*)- and (*Z*)-isoxazolidines which are oils. In order to determine





Fig. 1. The title molecule, including atomic numbering scheme, drawn using ORTEPII (Johnson, 1976). Displacement ellipsoids are plotted at the 50% probability level.

Experimental

A mixture of *N*-(4-fluorophenyl)-*C*-(3-nitrophenyl)nitrone (*1a*) (1.30 g, 5.00 mmol), toluene (20 ml) and styrene (0.52 g, 5.00 mol) was heated under reflux for 4 h. The solvent was removed from the hot mixture under reduced pressure and the residue was stored at 263 K for 3 d. Trituration of the resulting solid with light petroleum (b.p. 313–333 K) gave a pale buff, amorphous solid which was identified as a mixture of (*E*)- and (*Z*)-2-(4-fluorophenyl)-3-(3-nitrophenyl)-5-phenylisoxazolidine, (*2*) (ratio 8:94, ^{19}F NMR) (1.75 g, 4.81 mmol, 96%; found C 69.4, H 4.7, F 5.1, N 7.7%, M^+ 364; $C_{21}H_{17}FN_2O_3$ requires C 69.2, H 4.7, F 5.2, N 7.7%, M 364; m.p. 378–380 K). The major isomer was isolated by fractional crystallization (CCl_4 /light petroleum 1:1 v/v) and identified as (*Z*)-2-(4-fluorophenyl)-3-(3-nitrophenyl)-5-phenylisoxazolidine, (*2a*) (found: C 69.2, H 4.7, F 5.2, N 7.6%, M^+ 364; m.p. 383–384 K).

Crystal data

$C_{21}H_{17}FN_2O_3$	Mo $K\alpha$ radiation
$M_r = 364.38$	$\lambda = 0.71069 \text{ \AA}$
Monoclinic	Cell parameters from 20 reflections
$P2_1$	$\theta = 6.00\text{--}12.50^\circ$
$a = 5.556 (2) \text{ \AA}$	$\mu = 0.0929 \text{ mm}^{-1}$
$b = 15.332 (4) \text{ \AA}$	$T = 296 \text{ K}$
$c = 10.427 (4) \text{ \AA}$	Needle
$\beta = 90.47 (2)^\circ$	



$V = 888 (1) \text{ \AA}^3$
 $Z = 2$
 $D_x = 1.362 \text{ Mg m}^{-3}$

Data collection

CAD-4 diffractometer
 $\omega/2\theta$ scans
 Absorption correction:
 none
 1887 measured reflections
 1638 independent reflections
 856 observed reflections
 [$F > 3\sigma(F)$]
 $R_{\text{int}} = 1.36$

Refinement

Refinement on F
 $R = 0.0617$
 $wR = 0.0701$
 $S = 1.649$
 856 reflections
 244 parameters
 H-atom parameters not refined
 Weighting scheme based on measured e.s.d.'s
 $(\Delta/\sigma)_{\text{max}} = 0.0775$

$0.5 \times 0.1 \times 0.05 \text{ mm}$
 Colourless
 Crystal source: synthesized at UMIST

$\theta_{\text{max}} = 25.0^\circ$
 $h = 0 \rightarrow 6$
 $k = 0 \rightarrow 18$
 $l = -12 \rightarrow 12$
 3 standard reflections monitored every 150 reflections
 intensity decay: none

$\Delta\rho_{\text{max}} = 0.179 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.191 \text{ e \AA}^{-3}$
 Extinction correction:
 Zachariasen type 2
 Gaussian isotropic
 Extinction coefficient:
 $38 (1) \times 10^{-7}$
 Atomic scattering factors from *International Tables for X-ray Crystallography* (1974, Vol. IV)

N2—O1—C5 103.4 (7) N2—C3—C4 105.6 (9)
 O1—N2—C3 105.7 (7) C3—C4—C5 104 (1)
 O1—N2—C11 111.6 (8) O1—C5—C4 102.8 (8)
 C3—N2—C11 119.8 (9)

Data collection: *CAD-4 Diffractometer Control Software* (Enraf–Nonius, 1977). Cell refinement: *CAD-4 Diffractometer Control Software*. Data reduction: *PROCESS TEXSAN* (Molecular Structure Corporation, 1985). Program(s) used to solve structure: *SHELXS86* (Sheldrick, 1985). Program(s) used to refine structure: *LS TEXSAN*. Molecular graphics: *ORTEPII* (Johnson, 1976). Software used to prepare material for publication: *FINISH TEXSAN*. Literature search: *CSSR* (1984).

Lists of structure factors, anisotropic displacement parameters, H-atom coordinates and complete geometry have been deposited with the IUCr (Reference: HU1139). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

- CSSR (1984). *Crystal Structure Search and Retrieval Instruction Manual*. SERC Daresbury Laboratory, Warrington, England.
 DuBoisson, R. A. (1986). PhD thesis, Univ. of Manchester, England.
 Enraf–Nonius (1977). *CAD-4 Manual*. Enraf–Nonius, Delft, The Netherlands.
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
 Molecular Structure Corporation (1985). *TEXSAN. TEXRAY Structure Analysis Package*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
 Sheldrick, G. M. (1985). *SHELXS86*. In *Crystallographic Computing 3*, edited by G. M. Sheldrick, C. Krüger & R. Goddard, pp. 175–189. Oxford Univ. Press.

Table 1. Fractional atomic coordinates and equivalent isotropic displacement parameters (\AA^2)

$$U_{\text{eq}} = (1/3) \sum_i \sum_j U_{ij} a_i^* a_j^* \mathbf{a}_i \cdot \mathbf{a}_j.$$

	<i>x</i>	<i>y</i>	<i>z</i>	U_{eq}
O1	0.719 (1)	0.6692	0.5323 (6)	0.051 (3)
N2	0.890 (2)	0.7282 (7)	0.4764 (8)	0.058 (5)
C3	1.111 (2)	0.7185 (9)	0.553 (1)	0.059 (6)
C4	1.096 (2)	0.6271 (8)	0.614 (1)	0.071 (7)
C5	0.863 (2)	0.5898 (8)	0.559 (1)	0.069 (7)
C11	0.899 (2)	0.7191 (8)	0.343 (1)	0.051 (5)
C12	1.079 (2)	0.7620 (9)	0.271 (1)	0.060 (6)
C13	1.076 (2)	0.7613 (10)	0.141 (1)	0.068 (7)
C14	0.886 (3)	0.7182 (10)	0.075 (1)	0.076 (7)
C15	0.720 (2)	0.6748 (9)	0.140 (1)	0.064 (6)
C16	0.721 (2)	0.6765 (9)	0.275 (1)	0.064 (6)
C21	1.143 (2)	0.7896 (8)	0.6487 (10)	0.045 (5)
C22	0.978 (2)	0.8575 (8)	0.6619 (9)	0.048 (5)
C23	1.014 (2)	0.9175 (8)	0.760 (1)	0.058 (6)
C24	1.209 (2)	0.9144 (10)	0.844 (1)	0.067 (7)
C25	1.375 (2)	0.8497 (10)	0.829 (1)	0.075 (7)
C26	1.341 (2)	0.7858 (9)	0.732 (1)	0.069 (7)
C31	0.706 (2)	0.5343 (8)	0.643 (1)	0.057 (6)
C32	0.594 (2)	0.4629 (9)	0.588 (1)	0.061 (6)
C33	0.432 (3)	0.4165 (10)	0.662 (2)	0.088 (9)
C34	0.392 (3)	0.436 (1)	0.783 (2)	0.10 (1)
C35	0.510 (3)	0.504 (1)	0.839 (1)	0.089 (8)
C36	0.661 (3)	0.553 (1)	0.769 (1)	0.086 (9)
F14	0.884 (1)	0.7200 (7)	-0.0539 (7)	0.106 (5)
N23	0.841 (2)	0.9878 (8)	0.769 (1)	0.070 (6)
O23A	0.712 (2)	1.0065 (8)	0.678 (1)	0.097 (6)
O23B	0.823 (2)	1.0234 (8)	0.873 (1)	0.100 (6)

Table 2. Selected geometric parameters (\AA , $^\circ$)

O1—N2	1.44 (1)	C3—C4	1.54 (2)
O1—C5	1.49 (1)	C3—C21	1.49 (1)
N2—C3	1.47 (1)	C4—C5	1.52 (2)
N2—C11	1.40 (1)	C5—C31	1.50 (2)

Acta Cryst. (1995). C51, 1435–1438

4-(9,10-Dihydro-4*H*-benzo[4,5]cyclohepta[1,2-*b*]thien-4-ylidene)-1-methylpiperidinium Hydrogen Malate†

OSWALD M. PEETERS, NORBERT M. BLATON AND CAMIEL J. DE RANTER

Laboratorium voor Analytische Chemie en Medicinale Fysicochemie, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium

(Received 21 November 1994; accepted 23 December 1994)

Abstract

The title compound, $\text{C}_{19}\text{H}_{22}\text{NS}^+\text{C}_4\text{H}_5\text{O}_5^-$, is a drug used in the treatment of migraine. The tricyclic moiety is asymmetrically folded with a dihedral angle of

† Internal code of the Janssen Research Foundation: R21448.